Crohn's Disease (CD), a chronic subtype of Inflammatory Bowel Disease (IBD), affects the entire gastrointestinal tract but most commonly the terminal ileum and colon. Characterized by transmural inflammation, it leads to a range of symptoms including abdominal pain, diarrhea, fatigue, and weight loss. In the UK, approximately 0.31% to 0.35% of the population lives with Crohn's, translating to over 200,000 individuals, with prevalence rising with age and higher in rural areas and certain regions like the South West of England. Globally, millions suffer, but a major complication—intestinal fibrosis—remains poorly understood and untreated.

Fibrosis in Crohn's refers to the excessive deposition of extracellular matrix (ECM) components, primarily collagen, by activated fibroblasts and myofibroblasts. This scarring thickens the intestinal wall, narrows the lumen (fibrostenosis), and causes obstructive symptoms requiring intervention. Up to 50% of patients develop strictures within 10 years of diagnosis, with lifetime risks around 30-50%. Current management relies on endoscopic dilation or surgery, as no anti-fibrotic drugs exist for the gut, unlike lungs or liver.

🔬 A Collaborative UK Breakthrough in Mapping Fibrosis Drivers

Researchers from the Earlham Institute in Norwich, the University of Edinburgh, and Heriot-Watt University have published a pivotal study illuminating the cellular origins of submucosal fibrosis in fibrostenosing Crohn's. Titled "Crohn's lymphoid aggregates with endothelial clusters colocalise with submucosal fibrosis in fibrostenosing Crohn's disease," it appeared in The Journal of Pathology on March 16, 2026 (DOI: 10.1002/path.70019). This work, part of the Helmsley Charitable Trust-funded Gut Cell Atlas Project, integrates pathology, genetics, and computational biology to pinpoint actionable pathways.

Revolutionary Methods: Single-Cell RNA Sequencing Meets Histology

Single-cell RNA sequencing (scRNA-seq) profiles gene expression in individual cells, revealing heterogeneity invisible to bulk methods. The team analyzed clinical ileum samples from fibrostenosing Crohn's patients and controls, complementing traditional histology with scRNA-seq to identify disease-specific cell subpopulations and interactions.

Histological analysis confirmed maximal scar tissue in the submucosa—the layer beneath the mucosa. scRNA-seq data visualized via Uniform Manifold Approximation and Projection (UMAP) plots showed distinct clusters in diseased tissue.

This multi-omics approach, leveraging Earlham's data science expertise, links spatial pathology to molecular signaling, a gold standard in modern IBD research.

Core Finding: Crohn's Lymphoid Aggregates (CLAs) as Fibrosis Hubs

Inflammation recruits immune cells into submucosal Crohn's lymphoid aggregates (CLAs)—ectopic lymphoid structures unique to the disease. These CLAs colocalize with fibrosis hotspots, acting as orchestrators. Unlike typical lymphoid tissue, CLAs foster a pro-fibrotic niche.

• CLAs accumulate B cells, T cells, and macrophages in diseased submucosa.
• They correlate spatially with ECM deposition sites.
• Absence in non-fibrotic controls highlights specificity.

Endothelial Cell Clusters: The Unexpected Signalers

A striking discovery: atypical endothelial cell (lining blood vessels) clusters encircle CLAs. These express genes for pro-fibrotic ligands, signaling beyond vascular roles. Endothelial dysfunction, common in chronic inflammation, here promotes scarring.

Step-by-step: Inflammation → CLA formation → Endothelial clustering → Ligand secretion (e.g., VEGF, chemokines) → Recruitment/activation of macrophages and fibroblasts.

Photo by Osman Rana on Unsplash

Macrophages and Fibroblasts: Effectors of Scar Formation

Macrophages relay signals from endothelial clusters, polarizing to pro-fibrotic M2-like states releasing TGF-β (Transforming Growth Factor-beta), IL-6, and PDGF (Platelet-Derived Growth Factor). These activate fibroblasts into contractile myofibroblasts, ramping up collagen I/III synthesis.

This cascade explains why inflammation transitions to irreversible fibrosis.

Treatment Horizons: Targeting the New Pathways

With mechanisms mapped, therapies can target endothelial-CLA interactions or macrophage-fibroblast signaling. Anti-VEGF agents (repurposed from oncology) or TGF-β inhibitors show promise in preclinical models. Ongoing trials explore obefazimod's anti-fibrotic effects in IBD. For details on UK patient resources, visit Crohn's & Colitis UK.

Read the full Earlham Institute announcement here.

Spotlight: UK Institutions Leading IBD Research

The Earlham Institute excels in computational genomics, processing petabytes of single-cell data. University of Edinburgh's pathology expertise, led by Prof. Mark Arends, provides clinical grounding. Heriot-Watt contributes advanced imaging. This interdisciplinary model exemplifies UK higher education strengths.

Quotes: Dr. Gregory Wickham (Earlham): "This collaboration... reveal how cells coordinate to drive fibrosis." Prof. Irene Papatheodorou: "Mapping cellular neighborhoods... for new targets."

Single-Cell Tech Transforming Higher Ed Research

scRNA-seq, pioneered in UK labs, dissects complex tissues. Edinburgh's prior work on childhood-onset Crohn's gut development laid groundwork. Gut Cell Atlas expands this, aiding PhD/postdoc training in bioinformatics and pathology.

Challenges, Impacts, and Patient Stories

Fibrostenosis affects 10-20% early, surgery recurs in 30-50%. Patients face repeated operations, malnutrition. This study offers hope for prevention, improving quality of life.

Photo by Philipp Trubchenko on Unsplash

• Obstruction: 70% stricture surgeries.
• Costs: £millions NHS annually.
• Solutions: Early biomarker screening via CLA detection.

Future Outlook: From Atlas to Clinic

Next: Validate interactions in larger cohorts, spatial transcriptomics for dynamics. Pipeline drugs targeting TL1A, IL-11 may integrate these insights. UK unis position for grants, spinouts.

For those in higher ed, this underscores demand for skills in AI-driven omics.